ProMECE-CytaBOM vs MACOP-B in Advanced Aggressive Non-Hodgkin's Lymphoma: Long Term Results of a Multicenter Study of the Italian Lymphoma Study Group (GISL)
Vittorio Silingardi(University of Modena and Reggio Emilia), Caterina Mauri(University of Pavia), Carla Pieresca(Policlinico San Matteo Fondazione), Marco Lombardo(Vision Engineering (Italy)), Daniele Vallisa(Ospedaliera di Piacenza), Francesco Merli(Azienda Sanitaria Unità Locale di Reggio Emilia), Paolo Avanzini(Santa Maria Nuova Hospital), Luigi Cavanna(University of Pavia), M Carotenuto(Policlinico Universitario di Catania), Edoardo Ascari(University of Pavia), Paolo G. Gobbi(University of Pavia), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Massimo Federico(University of Modena and Reggio Emilia)
Cited by 22
Related Papers
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Distance as a Barrier to Cancer Diagnosis and Treatment: Review of the Literature
|The Oncologist|2015|531